Yihua He

Dr. Yihua He


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
DZDong Zhao
Dong Zhao
Yun ZhangYun Zhang
Yun Zhang
JWJiguang Wang
Jiguang Wang
LHLiu He
Liu He
YHYihua He
Yihua He
CMChangsheng Ma
Changsheng Ma

9 May 2025 in EBioMedicine
Verified
Journal Article
Open access
HSHairui Sun
Hairui Sun
XHXiaoyan Hao
Xiaoyan Hao
HLHankui Liu
Hankui Liu
SZSiyao Zhang
Siyao Zhang
JHJiancheng Han
Jiancheng Han
YHYihua He
Yihua He
Congenital heart disease (CHD) exhibits a marked male predominance in birth prevalence, yet the genetic mechanisms underlying this sex disparity remain poorly understood. This study investigates the contribution of rare damaging variants on autosomes and the X chromosome to sex differences in foetal CHD. Parents of foetuses with CHD were recruited for the study. Rare damaging variants were identified by analysing whole-exome sequencing data from foetus-parental trios, and their contributions to sex differences were estimated through case-control studies. Functional enrichment analysis was conducted to assess functional differences in genetic variants between sexes. 820 foetal probands with CHD were recruited, including 487 males and 333 females. We identified a significant enrichment of X-linked rare damaging variants, primarily driven by maternally inherited hemizygous variants (MIHVs) in male probands (OR = 1·84, P < 0·05), which accounted for 7·2% of male cases in our cohort. These variants were not found to be enriched in female probands. Additionally, X-linked rare damaging de novo variants (DNVs) were not enriched in either male or female probands (female probands: 1·8% versus female controls: 0·7%, P = 0·6789; no DNVs observed in males). Gene-level variant burden analysis revealed three X-linked CHD candidate genes: DCX, CACNA1F, and MAP3K15. Autosomal rare variants did not show significant differences in variant burdens between sexes. Notably, male probands showed specific functional enrichments in cilia-related pathways for autosomal recessive variants, as well as in chromatin remodelling and nervous system development pathways for autosomal DNVs. Male and female foetal CHD have significantly different genetic landscapes. The enrichment of X-linked rare damaging MIHVs in males provides a genetic explanation for the higher prevalence of CHD in males. This finding highlights the importance of incorporating sex-stratified approaches in clinical diagnostics and research. Natural Science Foundation of China and Key research and development project of Hebei Province.

3 January 2026 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
JZJingjing Zhou
Jingjing Zhou
YYYicheng Yang
Yicheng Yang
HZHuiyu Zou
Huiyu Zou
XJXiaolian Jiang
Xiaolian Jiang
WWWuming Wu
Wuming Wu
CDChunyan Deng
Chunyan Deng

24 March 2024 in Stem Cell Research
Verified
Journal Article
Open access
SZSiyao Zhang
Siyao Zhang
JFJiaqi Fan
Jiaqi Fan
HSHairui Sun
Hairui Sun
XHXiaoyan Hao
Xiaoyan Hao
YHYihua He
Yihua He
Tuberous Sclerosis Complex (TSC) is a severe developmental disorder with various clinical effects, primarily caused by TSC2 gene mutations, often involving loss of function(Henske,et al., 2016).To explore role of TSC2 in human heart development, we successfully developed a TSC2 knockout (TSC2-/-) human embryonic stem cells (hESCs) line using CRISPR/Cas9 gene editing. This TSC2-/- hESC line maintained a normal karyotype, expressed pluripotency markers strongly, and could differentiate into all three germ layers in vivo. This cell line will be a valuable tool for future research on the role of TSC2 in heart development.

8 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SZSiyao Zhang
Siyao Zhang
HSHairui Sun
Hairui Sun
XHXiaoyan Hao
Xiaoyan Hao
XZXu Zhi
Xu Zhi
RLRuimin Liu
Ruimin Liu
YHYihua He
Yihua He
Background: Congenital myocardial hypoplasia affects heart function in congenital heart diseases, but its causes and mechanisms are unclear. Methods: Fetuses with myocardial hypoplasia were examined using echocardiography imaging and genetic testing. The identified pathogenic genes were genetically targeted to validate mechanistic findings. We used stem cells and transgenic mice to understand molecular mechanisms and applied Preimplantation Genetic Testing for monogenic defects to obtain healthy offspring. In addition, 1,300 genetic sequencing records were screened to understand the prevalence of the disease and deepen our understanding of myocardial hypoplasia treatment. Results: This is the first study to link PFKP pathogenic variant to human myocardial hypoplasia. We found that PFKP deficiency decreased embryonic heart glycolysis, resulting in a thinning myocardial wall and impaired cardiac function, attributable to a decline in cardiomyocyte proliferation. The intrauterine supplement with Fructose 1,6-bisphosphate, a direct product of PFKP catalysis, can rescue the main myocardial phenotype of fetal mice. Assisted reproductive technology was used to prevent PFKP pathogenic variant transmission to offspring. Finally, one of the family lines (family 1) obtained a healthy offspring with a normal heart. Conclusions PFKP plays a key role in regulating glycolysis during embryonic cardiac development. Addressing glycolytic defects is crucial for myocardial hypoplasia. We provide new insights that have implications for genetic interventions, prenatal screening, and targeted intervention strategies.

1 July 2026 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
SZSiyao Zhang
Siyao Zhang
HSHairui Sun
Hairui Sun
XZXu Zhi
Xu Zhi
XHXiaoyan Hao
Xiaoyan Hao
JFJiaqi Fan
Jiaqi Fan
YHYihua He
Yihua He
This study reports a congenital heart disease, characterized by ventricular wall thinning and septal defects, caused by a heterozygous missense mutation (R755 W) in the glycolytic gene PFKP (platelet isoform of phosphofructokinase-1). The pathogenic mechanism involves the PFKP mutation impairing enzyme activity, which inhibits cardiomyocyte proliferation and leads to the thinning of the compact myocardium. In the mouse model, we found that administering the downstream metabolite, fructose-1,6-bisphosphate, reversed the myocardial hypoplasia in fetal mice, providing proof-of-concept for in utero intervention. Clinically, we successfully prevented the transmission of the disease using preimplantation genetic testing, resulting in the birth of a healthy infant.